

EXPLANATORY MEMORANDUM TO

The Misuse of Drugs (Designation)(Amendment No.2) Order (Northern Ireland) 2015

2015 No. 228

1. Introduction

- 1.1. This Explanatory Memorandum has been prepared by the Department of Health, Social Services and Public Safety for Northern Ireland to accompany the Statutory Rule (details above) which is laid before the Northern Ireland Assembly.
- 1.2. The Statutory Rule is made under powers conferred by sections 7(4) of the Misuse of Drugs Act 1971. It will amend the Misuse of Drugs (Designation)(Amendment) Order (Northern Ireland) 2001 and is subject to the negative resolution procedure.

2. Purpose

- 2.1. The main purpose of the Order is to designate the synthetic opioid MT-45 and chemical stimulant 4,4'-DMAR as controlled drugs to which section 7(4) of the 1971 Act applies and to be placed in Schedule 1 of The Misuse of Drugs (Designation) Order (Northern Ireland) 2001.

3. Background

- 3.1. The Misuse of Drugs (Designation) (Amendment No.2) Order (Northern Ireland) 2015 insert MT-45 and chemical stimulant 4,4'-DMAR in Schedule 1 of The Misuse of Drugs (Designation) Order (Northern Ireland) 2001. These are substances to which section 7(4) of the 1971 Act applies. This is because they have no recognised medicinal use beyond potential research which may be enabled under a licence.

4. Consultation

- 4.1. The Advisory Council on the Misuse of Drugs (ACMD) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been consulted and have advised there is no known medicinal use of these compounds in the UK.

5. Equality Impact

- 5.1. The outcome of the Home Office's equality impact assessment of the policy proposals is that no human rights engagements are anticipated as a result of the policy. In Northern Ireland the Department has screened the policy for the purposes of section 75 of the Northern Ireland Act 1998, and has concluded that an EQIA is not necessary.

6. Regulatory Impact

- 6.1. The Order applies to businesses selling substances in the 'legal highs' market, the potential harm is such that those trading in this market are expected to comply with the new legislative requirements or face prosecution.

7. Financial Implications

- 7.1. The potential impact on businesses and organisations including charities relates to the administrative costs of undertaking activities involving Class A drugs under licence for the purpose of research. These costs are likely to be minimal for organisations already licensed for similar activities involving other controlled drugs.

8. Section 24 of the Northern Ireland Act 1998

- 8.1. Consideration has been given to the human rights implications of these regulations. They are considered compatible with section 24 of the Northern Ireland Act 1998.

9. EU Implications

- 9.1. Not applicable

10. Parity or Replicatory Measure

- 10.1. The provisions included in the Order will bring Northern Ireland into line with measures that were introduced for the rest of the UK from 11th March 2015.

11. Additional Information

- 11.1. Not applicable